Effects of Betaserc on Vestibular Compensation in Patients Suffering From Disabling Meniere's Disease and Having Undergone Vestibular Neurotomy

Solvay

Status and phase: Completed; Phase 4

Conditions: Meniere's Disease

Treatments: Drug: Betahistine 24 mg bid (Betaserc)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00160238

S108.4.102

Details and patient eligibility

About

This study is to compare the effects of Betaserc 24mg and placebo on compensation of postural and locomotor deficits (static and dynamic posturography) after vestibular neurotomy in patients suffering from disabling Menière's disease.

Sex: All

Ages: 18 to 65 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients who have undergone vestibular neurotomy for the treatment of disabling Menière's disease and who have confirmed vestibular areflexia

Exclusion criteria

• Other peripheral vestibular disease than Menière's disease
• Central vestibular disease
• Neurological disease
• Contraindication to betahistine
• Pregnant or lactating women

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Double Blind